Samsung Biologics, KAHR Medical Sign Strategic Agreement for Cancer Immunotherapy Drug

According to a June 2, 2021 press release, Samsung Biologics and KAHR Medical have signed a strategic development and manufacturing agreement for a cancer immunotherapy drug candidate.

As per the terms of the agreement, Samsung Biologics—a contract development and manufacturing organization (CDMO)—will provide end-to-end cell line development and clinical drug substance and drug product manufacturing services for KAHR’s—a cancer immunotherapy company—drug candidate, DSP502. Additionally, Samsung Biologics will provide support to KAHR for its investigational new drug (IND) filing.

“We are proud to announce our partnership with KAHR Medical for the production of their novel drug candidate,” said John Rim, CEO of Samsung Biologics, in the press release. “We will leverage our fully integrated, scalable, and high-quality development services and experienced teams to enable a faster transition from gene to IND in order to ensure KAHR’s success in bringing cutting edge immuno-recruitment cancer drugs to patients in need.”

“We are very pleased to partner with Samsung Biologics, which is recognized as a leader in biopharmaceutical process development and manufacturing,” added Yaron Pereg, PhD, CEO of KAHR, in the press release. “DSP502 focuses on promising checkpoint pathways, unleashing the potential of the immune system to enhance anti-tumor immunoactivity through dual checkpoint inhibition.”

Source: Samsung Biologics